Brian P Brennan1, J Eric Jensen2, Christine Perriello3, Harrison G Pope4, Michael A Jenike5, James I Hudson4, Scott L Rauch6, Marc J Kaufman2. 1. Biological Psychiatry Laboratory, McLean Hospital, Belmont, MA; Obsessive-Compulsive Disorders Institute, McLean Hospital, Belmont, MA; Department of Psychiatry, Harvard Medical School, Boston, MA. 2. Department of Psychiatry, Harvard Medical School, Boston, MA; McLean Imaging Center, McLean Hospital, Belmont, MA. 3. Biological Psychiatry Laboratory, McLean Hospital, Belmont, MA. 4. Biological Psychiatry Laboratory, McLean Hospital, Belmont, MA; Department of Psychiatry, Harvard Medical School, Boston, MA. 5. Obsessive-Compulsive Disorders Institute, McLean Hospital, Belmont, MA; Department of Psychiatry, Harvard Medical School, Boston, MA. 6. Department of Psychiatry, Harvard Medical School, Boston, MA.
Abstract
BACKGROUND: Several lines of evidence support the hypothesis that lower cerebral levels of glutathione (GSH), associated with increased oxidative stress, may contribute to obsessive-compulsive disorder (OCD). However, no studies to date have investigated brain GSH levels in individuals with OCD. METHODS: Twenty-nine individuals with OCD and 25 age-, sex-, and race-matched comparison individuals without OCD underwent single voxel 2D J-resolved proton magnetic resonance spectroscopy (MRS) to examine GSH levels in the posterior cingulate cortex (PCC). MRS data were analyzed using LCModel and a simulated basis set. Group metabolite differences referenced to total creatine (Cr), as well as relationships between metabolite ratios and symptom severity as measured by the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), were analyzed using linear regression with adjustment for age, sex, and race. RESULTS: One OCD participant failed to produce usable PCC MRS data. We found significantly lower PCC GSH/Cr in OCD participants compared with non-OCD participants (β = -0.027 [95% CI: -0.049 to -5.9 × 10-3]; P = 0.014). PCC GSH/Cr was not significantly associated with total Y-BOCS score in the OCD group (β = 5.7 × 10-4 [95% CI: -4.8 × 10-3 to 5.9 × 10-3]; P = 0.83). CONCLUSIONS: Lower PCC GSH/Cr may be indicative of increased oxidative stress secondary to hypermetabolism in this brain region in OCD. Future MRS studies are warranted to investigate GSH levels in other brain regions that comprise the cortico-striato-thalamo-cortical circuit thought to be abnormal in OCD.
BACKGROUND: Several lines of evidence support the hypothesis that lower cerebral levels of glutathione (GSH), associated with increased oxidative stress, may contribute to obsessive-compulsive disorder (OCD). However, no studies to date have investigated brain GSH levels in individuals with OCD. METHODS: Twenty-nine individuals with OCD and 25 age-, sex-, and race-matched comparison individuals without OCD underwent single voxel 2D J-resolved proton magnetic resonance spectroscopy (MRS) to examine GSH levels in the posterior cingulate cortex (PCC). MRS data were analyzed using LCModel and a simulated basis set. Group metabolite differences referenced to total creatine (Cr), as well as relationships between metabolite ratios and symptom severity as measured by the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), were analyzed using linear regression with adjustment for age, sex, and race. RESULTS: One OCDparticipant failed to produce usable PCC MRS data. We found significantly lower PCC GSH/Cr in OCDparticipants compared with non-OCDparticipants (β = -0.027 [95% CI: -0.049 to -5.9 × 10-3]; P = 0.014). PCC GSH/Cr was not significantly associated with total Y-BOCS score in the OCD group (β = 5.7 × 10-4 [95% CI: -4.8 × 10-3 to 5.9 × 10-3]; P = 0.83). CONCLUSIONS: Lower PCC GSH/Cr may be indicative of increased oxidative stress secondary to hypermetabolism in this brain region in OCD. Future MRS studies are warranted to investigate GSH levels in other brain regions that comprise the cortico-striato-thalamo-cortical circuit thought to be abnormal in OCD.
Authors: Koji Aoyama; Sang Won Suh; Aaron M Hamby; Jialing Liu; Wai Yee Chan; Yongmei Chen; Raymond A Swanson Journal: Nat Neurosci Date: 2005-11-27 Impact factor: 24.884
Authors: S Evelyn Stewart; Jesen A Fagerness; Jill Platko; Jordan W Smoller; Jeremiah M Scharf; Cornelia Illmann; Eric Jenike; Nadia Chabane; Marion Leboyer; Richard Delorme; Michael A Jenike; David L Pauls Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2007-12-05 Impact factor: 3.568
Authors: Joseph O'Neill; John Piacentini; Susanna Chang; Ronald Ly; Tsz M Lai; Casey C Armstrong; Lindsey Bergman; Michelle Rozenman; Tara Peris; Allison Vreeland; Ross Mudgway; Jennifer G Levitt; Noriko Salamon; Stefan Posse; Gerhard S Hellemann; Jeffry R Alger; James T McCracken; Erika L Nurmi Journal: Neuropsychopharmacology Date: 2017-04-04 Impact factor: 7.853
Authors: S Andrea Wijtenburg; Jamie Near; Stephanie A Korenic; Frank E Gaston; Hongji Chen; Mark Mikkelsen; Shuo Chen; Peter Kochunov; L Elliot Hong; Laura M Rowland Journal: J Magn Reson Imaging Date: 2018-04-16 Impact factor: 4.813
Authors: Amy L Friedman; Ashley Burgess; Karthik Ramaseshan; Phil Easter; Dalal Khatib; Asadur Chowdury; Paul D Arnold; Gregory L Hanna; David R Rosenberg; Vaibhav A Diwadkar Journal: Psychiatry Res Neuroimaging Date: 2016-12-13 Impact factor: 2.376
Authors: Brian P Brennan; Roee Admon; Chris Perriello; Erin M LaFlamme; Alison J Athey; Diego A Pizzagalli; James I Hudson; Harrison G Pope; J Eric Jensen Journal: Psychiatry Res Neuroimaging Date: 2017-09-01 Impact factor: 2.376
Authors: Molly F Charney; David R Howell; Corey Lanois; Tyler C Starr; Huijun Liao; Eduardo Coello; Katherine M Breedlove; William P Meehan; Inga Koerte; Alexander P Lin Journal: J Head Trauma Rehabil Date: 2020 Sep/Oct Impact factor: 3.117
Authors: Ilse I G M van de Vondervoort; Houshang Amiri; Muriel M K Bruchhage; Charlotte A Oomen; Nitin Rustogi; Jason D Cooper; Jack J A van Asten; Arend Heerschap; Sabine Bahn; Steven C R Williams; Jan K Buitelaar; Geert Poelmans; Jeffrey C Glennon Journal: Transl Psychiatry Date: 2019-09-12 Impact factor: 6.222